Issue Date: July 17, 2017
CordenPharma, GE form oligonucleotide services pact
CordenPharma International and GE Healthcare’s Dharmacon division are joining to provide what they call an end-to-end service for oligonucleotide-based drug discovery. The GE unit offers custom synthesis of complex oligos to support research. CordenPharma provides larger-scale oligos manufacturing, a service it launched last year after investing in a Boulder, Colo., plant it acquired from Roche in 2011. CordenPharma currently supports early-stage clinical development and expects to begin commercial-scale manufacturing by the end of the year.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society